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Abstract The mouse mammary gland is a complex tissue
that proliferates and differentiates under the control of
systemic hormones during puberty, pregnancy and lacta-
tion. Once a highly branched milk duct system has been
established, during mid/late pregnancy, alveoli, little saccu-
lar outpouchings, sprout all over the ductal system and
differentiate to become the sites of milk secretion. Here, we
review the emerging network of the signaling pathways that
connects hormonal stimuli with locally produced signaling
molecules and the components of intracellular pathways
that regulate alveologenesis and lactation. The powerful
tools of mouse genetics have been instrumental in uncover-
ing many of the signaling components involved in
controlling alveolar and lactogenic differentiation.
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Abbreviations
WAP whey acidic protein
XIAP x-linked inhibitor of apoptosis protein
GH growth hormone
PTHrP parathyroid hormone related peptide
GR glucocorticoid receptor
ER estrogen receptor
PR progesterone receptor
PrlR prolactin receptor
RANKL receptor activator of NFκB ligand
EGF epidermal growth factor
HRG1 heregulin 1
GAS g-interferon activation sequence
JAK2 janus 2 kinase
SOCS suppressor of cytokine signaling proteins
STAT signal transducer and activator of transcription
C/EBP CCAAT/enhancer binding proteins
CDK cyclin dependent kinase
MMTV mouse mammary tumor virus
LMO4 LIM domain only 4
ErbB4 v-erb-a erythroblastic leukemia viral oncogene
homolog 4
ID2 inhibitor of DNA binding 2
Ets v-ets erythroblastosis virus E26 oncogene
homolog 1
ELF-5 E74-like factor 5
IGF-2 insulin-like growth factor 2
ERK1 extracellular-signal-regulated kinase 1
IKKα Inhibitor of kappa B kinase alpha
The mammary gland is the only organ that undergoes most
of its development postnatally. During embryogenesis, a
rudimentary ductal system develops. Under the influence of
systemic hormones at puberty the ducts begin to expand
into the surrounding stroma, the mammary fat pad,
(Fig. 1a). With repeated estrous cycles and during preg-
nancy, the complexity of the ductal system increases
through the addition of side branches (Fig. 1b; [1]). Finally,
at mid/late pregnancy (day 14.5 in 129SV and C57Bl6
background), alveoli, form all over the ductal system
(Fig. 1c). Alveoli are anatomical structures that have the
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form of a hollow cavity. They are also found in the terminal
portions of other secretory organs such as the salivary gland
and the pancreas and form grape-like structures at the end
of bronchioles in the lung. The mammary alveoli develop
into clusters by day 16.5 of pregnancy, and are dilated by
the pressure of the secretions produced by the epithelial
cells at the end of pregnancy (Fig. 1d; [1]).
This last stage of mammary gland morphogenesis,
alveologenesis, is closely intertwined with the functional
differentiation of the mammary epithelium called lacto-
genesis. Two stages of lactogenesis are distinguished. Stage
1 of lactogenesis [2] begins at mid-pregnancy and involves
increased and sustained expression of genes involved in the
synthesis of different milk proteins such as β-casein,
lactalbumin and WAP. Expression of various milk protein
genes increases transiently during the estrous cycles [3].
Morphologically, stage 1 is characterized by intracellular
lipid droplets (Fig. 1e). The second stage of lactogenesis
occurs around parturition; expression of milk protein genes
increases further, tight junctions between alveolar cells
close, and cytoplasmic lipid droplets and casein move to the
alveolar lumen ([4, 5]; Fig. 1f).
The observation that an early full-term pregnancy
protects against breast cancer [6] has stimulated efforts to
understand the events leading to full differentiation of the
mammary gland. Many of the pathways involved in
alveologenesis and lactogenic differentiation have been
uncovered in recent years using genetically engineered
mouse strains [7, 8], whereas the mechanisms underlying
alveologenesis in the pancreas and salivary gland are
largely unexplored.
Initially, gene targeting was used to delete genes in the
mouse germ line [9]. The analysis of the role of a given
gene product in the mammary gland can be confounded by
Figure 1 Mouse mammary
gland development during pu-
berty, pregnancy and lactation,
shown are whole mount micro-
graphs. At the onset of puberty
the rudimental ductal system
invades and eventually fills the
fat pad (a). With repeated es-
trous cycles and during the first
half of pregnancy side branches
form (b). During mid pregnancy
the alveolar structures sprout
from the expanded ductal tree
(c). During lactation, alveoli are
fully matured with distended
ductal lumen and secrete milk
(d). Hematoxylin and eosin
stained section of mammary
gland at day 14.5 of pregnancy.
Note the presence of intracellu-
lar lipid droplet characteristic of
this stage (e). The section of
lactating mammary gland, arrow
indicates the alveolar lumen
filled with lipid droplets (f).
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systemic effects of gene inactivation. To circumvent this
problem, transplantation techniques are used; mammary
epithelium and/or mammary gland stroma, the fat pad, from
donors of different genotypes are surgically recombined
within wild-type (wt) host [10, 11]. Another caveat of the
classical gene targeting approach is that the role of a gene at
a specific stage cannot be discerned if the deletion has
deranged earlier stages of development. This problem has
been elegantly solved with the generation of inducible/
conditional mouse mutant models. For example, during
alveologenesis and lactogenic differentiation, genes can be
specifically deleted by flanking the alleles with loxP binding
sites. These sites are recognized by the Cre recombinase
which can be expressed under the whey acidic protein (WAP)
promoter [12] that is expressed in mammary epithelial cells
undergoing secretory differentiation during pregnancy. The
use of WAP and other promoters, for example MMTV, to
drive the specific expression of the Cre recombinase has
been instrumental in defining the role of numerous gene
products in the mammary epithelium. Furthermore, such
work has revealed that the organism is extremely plastic
and able to compensate for germ-line mutations throughout
development. Thus, in the case of X-linked inhibitor of
apoptosis protein (XIAP) [13] as well as the transcription
factor LMO4 [14] (see below), germ line deletion of these
genes did not affect mammary gland development. In
contrast, when either of these genes was deleted specifically
during pregnancy milk secretion was impaired [13].
Hormonal Control of Alveologenesis
and Lactogenic Differentiation
A series of systemic factors influence the mammary gland.
Among them are the ovarian hormones estrogen and
progesterone, pituitary prolactin, placental lactogens as
well as the metabolic hormones, thyroid hormone, growth
hormone (GH) and corticosteroids. In recent years evidence
has accumulated that the mammary gland itself can secrete
hormones such as prolactin [15], GH [16], leptin [17] and
parathyroid hormone related peptide (PTHrP) [18]. PTHrP
reaches the bloodstream and is involved in triggering
calcium release from the bone during lactation. The local
secretion of prolactin, was shown to influence mammary
epithelial cell proliferation by an auto/paracrine mechanism
[19], and it is generally held that GH and leptin also act
within the mammary gland.
Adrenal glucocorticoids exert their biological activity by
binding to their cognate receptors, glucocorticoid receptor
(GR) and mineralocorticoid receptor. Cell culture experi-
ments have long implicated corticosteroids as lactogenic
factors [20]. Surprisingly, a recently developed mouse
model in which the epithelial GR was deleted during
pregnancy revealed that the receptor is dispensable for milk
production but required for proliferation of mammary
epithelial cells in vivo [21]. When the GR gene was deleted
in the mammary epithelium by means of a WAP–Cre trans-
gene, the cells showed reduced proliferation at day 14.5 of
pregnancy but increased proliferation after parturition [21].
The mechanisms by which corticosteroids affect epithelial
proliferation are unclear.
Another metabolic hormone, thyroid hormone, has also
been shown to be important for lactogenesis [22], but
whether it exerts its effect directly on the mammary gland
or indirectly by regulating other signaling pathways is
currently unclear.
Estrogen acts via two receptors, estrogen receptors α and
β, (ERα and ERβ) [23, 24], both of which are expressed in
the mammary gland [25–27]. ERα deficient mice are
completely infertile [28]. Tissue recombination experiments
revealed that ERα signaling is required in the mammary
epithelium for ductal elongation during puberty [29]. When
ERα deficient epithelium was grafted to cleared fat pads of
wildtype hosts, expression of milk protein genes were
induced during pregnancy [29], suggesting that ERα is not
required for transcriptional response to lactogenic stimuli.
ERβ deficient virgin females have ovarian defects, the rare
mutants that got pregnant and lactated successfully had
more dilated alveoli compared to wildtype animals [30].
Tight junctions between luminal epithelial cells were
impaired, and extracellular matrix and basal lamina were
reduced [30]. Whether this phenotype reflects a role of
ERβ signaling during mammary epithelial differentiation,
or whether it is a consequence of endocrine disturbances
in the ERβ mutant mice needs further clarification.
Progesterone actions are mediated by two protein
isoforms of the progesterone receptor PRA and PRB that
are derived by transcription from two distinct promoters of
the same gene. The longer B-form has an amino terminal
extension containing a transactivation function that
accounts for differential coactivator recruitment between
the two forms. Tissue recombination studies with proges-
terone receptor (PR) knockout tissues [31] revealed that
epithelial PR signaling is required for side branching and
alveologenesis [10]. Elegant gene targeting experiments in
which either the PRA or the PRB isoform were inactivated
in the germ line revealed that deletion of the longer PRB
form phenocopied the complete PR mutant mammary
gland, whereas absence of the shorter PRA form did not
impair mammary gland development [32], indicating that
PRB is the predominant mediator of progesterone action in
the mammary gland.
Other studies have demonstrated that PR is required only
in a subset of mammary epithelial cells during develop-
ment. Using mammary transplantation techniques, these
studies further demonstrated that WT epithelium, placed
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adjacent to PR−/− epithelium, can mediate alveologenesis
and lactogenic differentiation in the knockout tissue,
arguing for a paracrine signaling function for PR in the
gland during alveologenesis [10].
The two ovarian hormones, estrogen and progesterone
orchestrate the unfolding of the ductal tree thereby setting
the stage for alveolgenesis. The metabolic hormones appear
to reinforce different stages of mammary gland develop-
ment. The master controller of alveologenesis and lacto-
genic differentiation, however, is the pituitary polypeptide
hormone, prolactin. In the absence of epithelial prolactin
signaling, a fully branched ductal system develops but
alveologenesis fails to occur and the mammary epithelium
does not undergo secretory differentiation [33]. Indeed,
females heterozygous for the inactivated PrlR allele, show a
retardation in alveolar development and fail to feed their
first litter [34]. The central importance of this signaling
cascade is further underlined by the finding that loss of
principal downstream mediators, JAK2 and STAT5a/b [35–
38] and negative modulators, such as SOCS1 and 2, all
have effects on alveologenesis (see below).
Not only is the Prolactin/JAK2/STAT5 cascade crucial
for the functional differentiation of the mammary gland, but
it also controls related events in other organs. Acting on
pancreatic β-cells, prolactin triggers cell proliferation and
insulin secretion thereby ensuring a series of metabolic
adjustments required for milk secretion [39]. Hypothalamic
neuroendocrine dopaminergic neurons increase dopamine
turnover in response to prolactin. They release dopamine,
which subsequently inhibits prolactin release from the
anterior pituitary, functioning as a negative feedback loop
[40].
Figure 2 Model of the signal-
ing network that controls alveo-
logenesis and lactogenic
differentiation in the mouse
mammary gland. The model is
based on studies of different
mouse mutant models discussed
in the text.
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Auto- and Paracrine Factors
Several local factors have been implicated in alveolo-
genesis. Insulin-like growth factor 2 (IGF-2) was identified
in an expression screen for prolactin-dependent genes in
vivo and shown to be induced in primary mouse mammary
epithelial cells by prolactin [41]. Analysis of IGF-2
deficient mice and ectopic expression of IGF-2 in PrlR−/−
epithelia suggested that IGF-2 is involved specifically in
alveolar morphogenesis, but not in the secretory differen-
tiation of mammary epithelial cells (see Fig. 2).
Receptor activator of NFκB ligand, (RANKL) is a
cytokine long known to be essential for the maturation of
antigen-presenting cells and osteoclasts. Deletion of
RANKL or its receptor RANK from the mammary
epithelium blocked alveologenesis and lactogenic differen-
tiation [42]. The RANKL promoter region contains a g-
interferon activation sequence (GAS) that conferred a
STAT5 and JAK2 dependent prolactin response in reporter
assays consistent with RANKL being a prolactin target
gene [43]. In vivo, both progesterone [32, 41] and prolactin
[43] have been linked to RANKL transcriptional control.
The importance of different downstream signaling events is
currently unclear. In the mammary epithelia of RANKL−/−
mice, activation of STAT5 and ERK1/ERK2 was unaffected
but AKT phosphorylation was decreased [42]. Based on
these observations, together with their findings that apo-
ptosis was increased and proliferation decreased in mam-
mary epithelia of pregnant RANKL−/− mice, Fata et al.
proposed that RANKL acts by inhibiting apoptosis via
activation of the PI3kinase pathway. Cao et al. showed that
IKKα is an important downstream mediator of RANKL
and that RANKL affects proliferation via NFκB/Cyclin D1
[44]. However, biochemical evidence demonstrating the
induction of Cyclin D1 by RANKL in the mammary
epithelium is still missing [41, 45, 46]. And, recently the
observation was made that mammary epithelial cells of
RANKL−/−mice have normal cyclin D1 expression [45, 46].
Thus, the mechanism by which RANKL/RANK signaling
contributes to alveologenesis and lactogenic differentiation
warrants further studies.
Another locally produced factor important to both
alveologenesis and lactogenic differentiation is the epider-
mal growth factor (EGF) family member, heregulin; more
specifically, the HRG1 isoform expressed in the mammary
gland, HRGα. Deletion of HRGα selectively impaired
alveologenesis and lactogenic differentiation. The number
of alveoli in HRGα deficient females was decreased, they
were less distended and milk gene expression was reduced.
Nevertheless, mutant mothers, were able to feed their pups
[47], possibly because other ErbB ligands compensate for
the absence of HRGα. Indeed, deletion of a conditional
allele of the receptor, ErbB4, during pregnancy with a
WAP–Cre transgene impairs alveologenesis and lactogenic
differentiation more severely with only 20% of the
offspring surviving [47]. The other cognate HRGα recep-
tor, ErbB2, was inactivated by ectopic expression of a
dominant negative mutant and resulted in a similar
phenotype [48] consistent with the HRG/ErbB pathway
being important in both alveologenesis and lactogenic
differentiation.
Intracellular Signal Transduction
How does the cell react to all the stimuli it receives and
how does it integrate the different inputs? The intracellular
events are best understood in the case of prolactin
signaling. Binding of prolactin triggers receptor dimeriza-
tion. As a result, janus-2 kinase (JAK2) is recruited and
activated. The activated JAK2, in turn, phosphorylates both
the prolactin receptor and signal transducer and activator of
transcription 5 (STAT5). Two STAT5 proteins exist,
STAT5a and STAT5b, that share over 90% identity and
diverge only in their carboxyl terminus. STAT5a is the
predominant form in the mammary gland. Once activated,
STAT5 dimerizes and translocates to the nucleus where it
activates the transcription of target genes, such as different
milk protein genes that contain GAS (g-interferon activa-
tion sequence) in their promoters [49]. The suppressors of
cytokine signaling (SOCS) are also induced by STATs and
they negatively regulate cytokine signaling in two ways.
First, they bind to phosphotyrosines on cytokine receptors
via an SH2 domain, thereby competing with STATs.
Second, they recruit E3 ubiquitin ligases via a domain
called the SOCS box. This leads to ubiquitination of the
activator kinase, JAK2, which is subsequently degraded via
the proteasome.
In the mammary gland, loss of SOCS1 and SOCS2
accelerated alveologenesis and rescued the phenotype of
PrlR+/− mice, consistent with SOCS1 and SOCS2 exerting a
negative regulatory effect downstream in the PrlR signaling
pathway [50, 51].
Another negative regulator of prolactin signaling is
Caveolin-1. Caveolin family members are scaffold proteins
thought to organize and concentrate different lipids and
lipid modified proteins within caveola membranes. It was
observed that caveolin-1 is down modulated during late
pregnancy and lactation as a consequence of prolactin
signaling [52]. Indeed, overexpression of caveolin in HC11
cells reduced prolactin-induced activation of a β-casein
reporter. Deletion of caveolin-1 led to premature STAT5
activation, alveologenesis and milk protein gene expression
[53]. Caveolin-1 and -3 share conserved residues with
SOCS proteins in the pseudosubstrate domain that interacts
with JAK2 [53].
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Deletion of JAK2 resulted in embryonic lethality. To
analyze the role of its gene product in the mammary
epithelium, Shillingford et al. rescued mammary anlage
from JAK2−/− embryos by transplantation [36], whereas
Wagner et al. used an MMTV–Cre transgene to delete the
first coding exon, a floxed exon 2 [35]. In both mutant
models alveologenesis and lactogenic/secretory differentia-
tion were completely blocked, and STAT5 phosphorylation
was abrogated [35, 36] consistent with JAK2 being a
central mediator of PrlR signaling.
Germ line deletion of STAT5a affected the mammary
gland [54], resulting in impaired alveologenesis and lacto-
genesis whereas inactivation of STAT5b expressed at ten-
fold lower levels in the mammary gland [54], did not
adversely affect the organ [55]. Ablation of both STAT5a
and STAT5b strongly aggravated the phenotype [56];
STAT5 deficient mammary epithelia failed to form alveoli
and to express milk protein genes [38]. Interestingly, while
the PrlR deficient epithelium showed lumen formation in
the smallest ducts, the STAT5 deficient epithelial ducts
were not distended and, instead, had defects in cell–cell
contacts [38]. This indicates that STAT5 function is not
limited to mediating the effects of prolactin[57]. Indeed it
can be activated by a number of receptor tyrosine kinases
by Src dependent and independent mechanisms [58].
Moreover, deletion of STAT5 from the secretory epithelial
cells during pregnancy resulted in cell death indicating that
STAT5 function is not only required for the functional
differentiation of the mammary epithelial cells, but also for
their maintenance and survival [37]. Interestingly, STAT5
phosphorylation is strikingly reduced in ErbB4 deficient
mammary glands, although prolactin signaling appears to
be intact as assessed by STAT5 phosphorylation upon acute
prolactin treatment [47]. Prolonged progesterone treatment
induced STAT5 phosphorylation in the mammary epitheli-
um of PrlR−/− but not ErbB4−/− mice, suggesting that
ErbB4 is essential for STAT5 phosphorylation during late
pregnancy [47]. The significance of the ErbB4 versus PrlR-
induced STAT5 phosphorylation is unclear. One possibility
is that HRGα-induced ErbB4 activation functions as a
backup mechanism to ensure adequate STAT5 phosphory-
lation when PrlR signaling is down modulated via negative
feedback loops. It is not known whether PrlR and ErbB4
receptors are coexpressed on the same cells and, if they are,
whether they colocalize within cell membranes. Site
mapping has shown that ErbB4 phosphorylates STAT5 on
a residue distinct from those phosphorylated by the PrlR
[47, 59], suggesting that different signaling pathways are
activated by these receptors. Thus, it is conceivable that
both ErbB4 and PrlR activate STAT5 but in discrete cellular
compartments, leading to the activation of different down-
stream targets and, consequently, distinct biological out-
comes. Long et al. report that ErbB4 phosphorylates STAT5
on a residue distinct from those phosphorylated by the PrlR,
[47, 59] thus different protein–protein interactions could be
elicited resulting in differential activation of downstream
signaling pathways.
Recently, the ets transcription factor family member,
ELF-5, which is widely expressed in epithelia of exocrine
glands was established as a crucial mediator of prolactin
signaling in the mammary gland [60]. Deletion of this
transcription factor resulted in early embryonic lethality.
Heterozygote females were healthy but failed to lactate.
Transplantation experiments established that ELF-5 was
required in the mammary epithelium for alveologenesis and
milk protein expression both of which were strikingly
reduced in the mammary glands of heterozygote females
[61]. The levels of ELF-5 expression were reduced in
PrlR+/− mammary glands, conversely, PrlR expression
levels were not altered by decreased levels of ELF-5
consistent with this transcription factor being downstream
of prolactin signaling [61]. Ectopic expression of ELF-5 in
PrlR−/− epithelium rescued both alveologenesis and milk
gene expression indicating that this transcription factor can
substitute for prolactin signaling [51]. How ELF-5 relates to
STAT5 remains to be elucidated. Interestingly, in T-cells
STAT5 has been found to interact both physically and
functionally with the ELF-5 cousins Ets-1 and Ets-2 [62].
Another transcription factor required in the mammary
epithelium for both alveologenesis and lactogenic differen-
tiation is the helix-loop-helix inhibitor ID2 [46, 63, 64].
The absence of this transcription factor does not affect the
expression levels of C/EBPβ, cyclinD1, PrlR nor STAT5a
or b but was shown to substantially decrease STAT5 DNA
binding activity [63]. This suggests that ID2 modulates
STAT5 transcriptional activity downstream of prolactin
signaling. Recently, ID2 itself was shown to be downstream
of RANKL, and to be required for RANKL-induced
proliferation of mouse mammary epithelial cells in vitro
[46]. It was found in the nucleus of wildtype cells during
pregnancy, but it did not localize to nuclei in RANKL−/−
mammary epithelia [46]. These findings point to the
intriguing possibility that ID2 links RANKL and prolactin
signaling pathways.
The CCAAT/enhancer binding proteins (C/EBP) are part
of the family of leucine-zipper DNA binding (bZIP)
proteins and regulate transcription by binding as homo- or
heterodimers to a common nucleotide consensus site [65].
Mammary epithelium deficient for C/EBPβ fails to develop
alveoli and does not undergo lactogenic differentiation [3,
66]. This phenotype is difficult to interpret because the
preceding ductal morphogenesis was severely impaired
resulting in a less complex ductal system and dilated ducts
[66]. Moreover, expression levels of PR and PrlR were
increased and the expression pattern of these receptors, as
well as the response to hormonal stimulation, was altered
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[67] suggesting C/EBPβ is upstream of the hormonal
signaling pathways that control alveologenesis. Recent
work showed that C/EBPβ mediates β-casein induction
by RANKL and regulates the expression of ID2 [68]. These
observations indicate that several loops are built into the
intracellular signaling network that controls alveologenesis
and lactogenic differentiation.
Another transcription factor recently implicated in
alveologenesis and lactogenic differentiation is LMO4, a
member of the LIM-only family of zinc-finger proteins.
Deletion of floxed alleles of this gene during pregnancy by
means of a WAP–Cre transgene, partially blocks alveolo-
genesis and milk protein synthesis, mutant dams, however,
are still able to nurse their offspring [14]. How ELF5, ID2,
C/EBPβ, and LMO4 interact with each other, whether they
are active within the same cells and at the same promoters,
at the same time or sequentially are open questions.
Finally, loss of the X-linked inhibitor of apoptosis
protein (XIAP), a member of the inhibitor of apoptosis
proteins family of caspase inhibitors that selectively binds
and inhibits caspases-3, -7 and -9, results in impaired
lactogenic differentiation and alveolar morphogenesis [13].
The mutant mammary glands showed delayed STAT5
phosphorylation and NFkB activity.
Cyclin D1 and the GR are the only intracellular players
identified to date that selectively affect alveolar morpho-
genesis and not lactogenic differentiation [69]. Based on the
well-established role of D-type cyclins in G1 progression,
the failure of cyclin D1 deficient mice to undergo alveolo-
genesis was attributed to a defect in proliferation during
pregnancy[41, 70]. Recent findings that the mammary
defect of cyclin D1 deficient mice was rescued when the
gene is replaced by a cyclin D1 mutant that does not
interact with the cyclin dependent kinases 4 and 6 (CDK4
and CDK6) and hence cannot promote cell cycle progres-
sion [71] indicate that cyclin D1 has a role beyond its well-
established cell cycle regulatory function. Indeed, cyclin D1
has previously been shown to affect ER mediated tran-
scription albeit in overexpression studies [72, 73]. Unravel-
ing the new interactors and mediators of protein protein
interactions, cyclin D1 function in the mammary epithelium
should provide insights into the mechanisms underlying
alveologenesis.
Taken together a signaling network that emerges controls
alveologenesis and lactogenic differentiation in which
prolactin signaling is the central hub (Fig. 2).
Cell Adhesion
Over the past decade the importance of epithelial polarity
and adhesion for secretory function/differentiation has
become apparent. The interaction of mammary epithelial
cells with the extracellular matrix is mediated by integrins.
While mammary glands developed normally in the absence
of α3, or α6 integrins [74] deletion of β1-intgrin from the
mammary epithelium during pregnancy, resulted in reduced
alveologenesis, disrupted alveolar structure and reduced
expression of the milk protein β-casein [75, 76].
Similarly, deletion of α-catenin using a Cre transgene
under the control of either an MMTV or a WAP promoter,
resulted in a lactation defect. The mutant mothers devel-
oped alveolar structures that failed to expand. The luminal
cells showed defects in adhesion and loss of epithelial cell
polarity, and reduced milk protein gene expression. The
phenotype was more pronounced in MMTV–Cre deleted
than WAP–Cre deleted mutants [77]. Similarly, deletion of
E-cadherin by an MMTV–Cre transgene specifically affects
terminal differentiation. The phenotype became apparent
during pregnancy, because alveoli failed to expand in the
knockout mice, and histological sections revealed no fat
droplets. Further analysis confirmed this observation by
demonstrating that the milk protein genes, β-casein and
WAP, were expressed in the knockout at levels much lower
compared to wild type control and mothers were unable to
feed their pups [7].
Taken together, these observations indicate that intact
cell adhesion is a prerequisite for successful alveologenesis
and lactogenic differentiation. Why does the deletion of
such important adhesion molecules as E-cadherin or α-
catenin, have no obvious effect on ductal morphogenesis
but is clearly detrimental for alveologenesis and lactogen-
ic differentiation? A simple explanation might be that the
deletion efficiency is higher during pregnancy when the
MMTV promoter shows maximum activity than in the virgin
mouse. Alternatively, compensatory mechanisms might be
available that help the mammary epithelium to adjust to the
challenges of ductal morphogenesis, such as the SLITs/
Netrins [78]. Ultimately, these backup mechanisms fail
when the epithelium needs to withstand the pressure gen-
erated by the secretions that accumulate in the ducts as the
cells differentiate.
Outlook
Over the past 15 years, mouse genetics have revealed many
of the components of the signaling network that controls
alveologenesis and lactogenic differentiation (as illustrated
in Fig. 2). Further factors are likely to be identified and new
interactions between the signaling cascades and cellular
functions should be revealed.
There is a clear need for more conditional/inducible
mutant models. As has been illustrated by the comparison
of the germ line and conditional deletions of LMO4 and
XIAP, the mammary epithelium is fully capable of adapting
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to the lack of many different genes during development.
It is conceivable that novel functions of PR signaling and
C/EBPβ during alveologenesis and lactogenic differenti-
ation will be uncovered by deleting these genes specifi-
cally during late stages of mammary gland development.
Pursuing these questions will require new powerful indu-
cible models [79].
This review of the mammary gland has focused almost
exclusively on the targets of the prolactin signaling in the
luminal epithelial cells. Currently, we know little about
the physiological function of the myoepithelial cells and
the changes in the stroma required for alveologenesis and
lactogenic differentiation (for review, see July 2005 issue
of this journal). Evidence has accumulated that the myoepi-
thelium is more than an innocent bystander during breast
carcinogenesis [80] and the same seems to apply to devel-
opment [81]. Further insights will likely come from increas-
ingly complex 3D culture studies [82].
With regards to the stromal contribution new models are
needed. Many “stroma-specific” promoters express not only
in the mammary gland but are active in the connective
tissue of numerous organs, this limits their use in driving
Cre. Furthermore, we will need to refine our appreciation of
the stroma. Obviously, the stromal fibroblasts in contact
with the basal lamina have very different role from the fat
cells. Cell-type specific promoters used to drive Cre
transgenes will be instrumental to gaining new insights.
Capillary plexuses invest the secretory alveoli. How do
these develop? How is the establishment of new blood
vessels coordinated with epithelial outgrowth? Lymph flow
from the lactating gland is high, how is the lymph flow
established? Ever more powerful imaging techniques
provide new dynamic views of mammary gland develop-
ment in vivo that may provide answers to these questions.
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